IRLA

39.7050.59%
KR

Keith R. Fandrick

Chief Operating Officer

Dr. Keith Fandrick, Ph.D., is Chief Operating Officer of IRulya Therapeutics Inc. (formerly known as Quince Therapeutics, Inc.) from October 8, 2026 and was Head of Technical Operations until October 8, 2026. Dr. Fandrick serves as Chief Operating Officer at AI Therapeutics, Inc. He is the Member of Scientific Advisory Board at Drug Farm Inc. After graduation he joined the Chemical Development group at Boehringer Ingelheim where he was charged with the development of safe, economical and robust asymmetric synthesis of challenging compounds. His background and experience also include computational modeling with Quantum Mechanical/Density Function Theory. Dr. Fandrick has over 70 publications and patents and currently serves as the Head of Chemistry and CMC at AI Therapeutics.Prior to that time, Dr. Fandrick served as Chief Operating Officer of Orphai, where he led operations, chemistry, manufacturing and controls, program management, regulatory strategy, external manufacturing and intellectual property activities for clinical-stage therapeutic programs since 2017 and he previously served in various other roles at Orphai, including as Chief Development Officer and Head of CMC. Previously, Dr. Fandrick served as a member of the Scientific Advisory Board of Drug Farm, Inc., where he advised on pharmaceutical development and CMC strategy. From 2007 to 2017, Dr. Fandrick held positions of increasing responsibility at Boehringer-Ingelheim. Dr. Fandrick is an author or co-author of 78 publications and patents. He holds Ph.D. and A.M. degrees in chemistry from Harvard University, an M.B.A. from the University of North Carolina at Chapel Hill’s Kenan-Flagler Business School, a B.S. in chemistry from the University of California, San Diego and a Regulatory Affairs Certification.

Positions